Alpha Teknova, Inc. (TKNO) Market Cap
Alpha Teknova, Inc. has a market capitalization of $157M.
Financials based on reported quarter end 2025-12-31
Price: $2.93
▲ 0.25 (9.33%)
Market Cap: 157.01M
NASDAQ · time unavailable
CEO: Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
IPO Date: 2021-06-25
Website: https://www.teknova.com
Alpha Teknova, Inc. (TKNO) - Company Information
Market Cap: 157.01M · Sector: Healthcare
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Analyst Sentiment
Based on 6 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"TKNO reported revenue of $9.98M for the year ending December 31, 2025, but incurred a net loss of $4.76M. The company has total assets of $103.58M and total liabilities of $34.81M, resulting in equity of $68.78M. Investors should note that TKNO is currently unprofitable, with an earnings per share (EPS) of -$0.09. The cash flow from operations was $0, and free cash flow stood at -$348k, indicating cash management challenges. Despite these metrics, the stock has seen a significant decline, with a 1-year price change of -53.22%. This downward trend may raise concerns regarding investor confidence and the company's operational health. The absence of dividends further emphasizes the focus on growth and sustainability rather than immediate shareholder rewards. Overall, the company's financials depict a challenging scenario, where improvements in profitability and cash generation are necessary for a positive turnaround."
Revenue Growth
Revenue of $9.98M indicates modest growth potential but is still relatively low.
Profitability
Negative net income of $4.76M signals significant profitability issues.
Cash Flow Quality
Operating cash flow of $0 and negative free cash flow reflect serious cash management challenges.
Leverage & Balance Sheet
Total equity of $68.78M suggests a manageable leverage, with net debt of $9.23M.
Shareholder Returns
No dividends paid and a substantial decline in stock price indicate weak shareholder returns.
Analyst Sentiment & Valuation
Overall sentiment may be negative considering the declining stock price and financial struggles.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Teknova is exiting 2025 with strong operating metrics—Q4 revenue $10.0M (+8% YoY), gross margin 32.5% (vs 23.0% a year ago), and free cash outflow of -$9.8M, below its prior < $12M guidance. However, the Q&A exposes timing fragility behind management’s optimism. The company attributes growth to a biotech funding “4-quarter lag” (often 3–4 on the way down), and explicitly says biotech upside is not built into 2026. For adjusted EBITDA, they reiterate a path to positive by end-2027, but clarify the requirement: ~$13M–$14M revenue/quarter by then versus ~$10M–$11M at the 2026 guidance midpoint—meaning the market/ramp timing is the core uncertainty. Management’s tone is confident on 2027 demand (therapies moving toward commercialization), but analysts pushed hard on whether benefits will spill into 2026; management’s answer: potential upside exists, yet timing remains uncertain and therapy-dependent.
Growth Catalysts
- RUO Lab Essentials scale via increased active customers (60 clinical buyers; 25% more than 2024 for clinical products)
- Private label manufacturing expansion for larger customers in life science tools & diagnostics (sequencing, spatial genomics, cancer screening as stated targets)
- GMP-grade reagents support scaling as therapies move through trial phases (Phase I 12 and Phase II+ 5 as of end-2025; target 1 commercial therapy by end-2027)
Business Development
- Clinical Solutions suppliers supporting 60 clinical customers (50 biopharma-related) and 70+ therapies across those customers
- Private labeling / kit inclusion and bulk reagent supply for larger tool/diagnostics customers (no specific named partners disclosed)
- Commercial investment: hiring “a couple of people in the field” with relationships to target customer groups
Financial Highlights
- Q4 2025 revenue: $10.0M (+8% YoY) vs $9.3M (prior year); full-year revenue $40.5M (+7% YoY) vs $37.7M
- Gross margin: 32.5% in Q4 2025 (up from 23.0%); full-year gross margin 33.2% (up from 19.2%)
- Gross margin driver cited: higher Clinical Solutions revenue + manufacturing efficiency gains; full-year also benefited by $2.8M nonrecurring/noncash inventory disposal/write-down charges in 2024
- Adjusted EBITDA: -$1.8M in Q4 2025 (vs -$3.2M); full-year -$6.7M (vs -$14.5M)
- Free cash outflow: FY 2025 -$9.8M vs guidance < $12M; FY 2024 -$13.5M
- Cash/fin position at 12/31/2025: $21.3M cash/cash equivalents/short-term investments; $13.2M gross debt
Capital Funding
Strategy & Ops
- Raised 2026 sales & marketing investment by ~$2M (from continued prior cost structure) after 2 years of cost cutting
- Guidance/efficiency context: company states incremental revenue drops through at ~70% marginal cash rate (fixed-cost structure)
- Operating expense maintenance: operating expenses excluding nonrecurring charges were < $8M for the 7th consecutive quarter
- Automation/scale claim: already-made investments enable >$200M revenue with limited incremental operating/capex (no new capex dollar guidance beyond low 2025 levels)
Market Outlook
- 2026 revenue guidance: $42M to $44M (midpoint implies ~6% growth)
- 2026 gross margin guidance: mid-30s% range vs 33% in 2025 (based on midpoint revenue guidance)
- 2026 free cash outflow guidance: < $10M (due to increased commercial investment)
- Adjusted EBITDA annualized run-rate target at higher spend: positive in range of $52M to $57M annualized; expectation of a positive adjusted EBITDA quarter by end-2027
- EBITDA-positive mechanics clarified in Q&A: run-rate roughly $13M to $14M revenue per quarter needed by end-2027; at guidance midpoint this equates to ~$10M–$11M revenue/quarter (timing risk)
Risks & Headwinds
- Biotech funding recovery timing risk: management saw uptick in biotech funding in Q4 2025 and early Q1 2026 but wants evidence it is sustained before assuming recovery impact in 2026
- Not built into 2026 plan: stronger biotech funding upside not reflected in base guidance for 2026
- Clinical Solutions ramp uncertainty: investor pressure focused on lower average revenue per customer; management said timing is therapy-dependent and clinical trials can take 7–10 years
- Average revenue per customer down in 2025 driven by adding new clinical customers (Clinical Solutions ARPC down 14% to $128k); ramp lag risk if customer volume doesn’t scale as expected
Sentiment: MIXED
Note: This summary was synthesized by AI from the TKNO Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.